Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?Vaccine, 2017-08, Vol.35 (35), p.4470-4474 [Peer Reviewed Journal]2017 ;Copyright © 2017. Published by Elsevier Ltd. ;Copyright Elsevier Limited Aug 16, 2017 ;2017 Published by Elsevier Ltd. 2017 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2017.04.082 ;PMID: 28633891Full text available |
|
2 |
Material Type: Article
|
Healthcare providers as sources of vaccine-preventable diseasesVaccine, 2014-08, Vol.32 (38), p.4814-4822 [Peer Reviewed Journal]2014 ;Published by Elsevier Ltd. ;Copyright Elsevier Limited Aug 27, 2014 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2014.03.097 ;PMID: 24726251Full text available |
|
3 |
Material Type: Article
|
Comprehensive Control of Human Papillomavirus Infections and Related DiseasesVaccine, 2013-11, Vol.31 (8), p.I1-I31 [Peer Reviewed Journal]Elsevier Ltd ;2013 Elsevier Ltd ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Nov 22, 2013 ;2013 Elsevier Ltd. All rights reserved. 2013 ;ISSN: 0264-410X ;ISSN: 1873-2518 ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2013.07.026 ;PMID: 24229716Full text available |
|
4 |
Material Type: Article
|
A Review of Clinical Trials of Human Papillomavirus Prophylactic VaccinesVaccine, 2012-11, Vol.30 (5), p.F123-F138 [Peer Reviewed Journal]2012 ;Published by Elsevier Ltd. ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2012.04.108 ;PMID: 23199956Full text available |
|
5 |
Material Type: Article
|
The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next stepsVaccine, 2016-06, Vol.34 (26), p.2939-2947 [Peer Reviewed Journal]World Health Organization; licensee Elsevier ;2016 World Health Organization ;Copyright © 2016 World Health Organization. Published by Elsevier Ltd.. All rights reserved. ;Copyright Elsevier Limited Jun 3, 2016 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2016.03.111 ;PMID: 27105564Full text available |
|
6 |
Material Type: Article
|
Vaccine-preventable diseases: Immune response in a large population of healthcare studentsVaccine, 2024-02, Vol.42 (4), p.930-936 [Peer Reviewed Journal]2024 The Author(s) ;Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. ;2024. The Author(s) ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2024.01.038 ;PMID: 38246845Full text available |
|
7 |
Material Type: Article
|
Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional surveyVaccine, 2020-10, Vol.38 (45), p.7049-7056 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2020.09.021 ;PMID: 32980199Full text available |
|
8 |
Material Type: Article
|
A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet availableVaccine, 2014-03, Vol.32 (12), p.1326-1337 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 10, 2014 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2014.01.040 ;PMID: 24486372 ;CODEN: VACCDEFull text available |
|
9 |
Material Type: Article
|
Cost-effectiveness of adult vaccinations: A systematic reviewVaccine, 2019-01, Vol.37 (2), p.226-234 [Peer Reviewed Journal]2018 ;Published by Elsevier Ltd. ;Copyright Elsevier Limited Jan 7, 2019 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2018.11.056 ;PMID: 30527660Full text available |
|
10 |
Material Type: Article
|
The effect of Bacillus Calmette–Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for the COVID-19 pandemicVaccine, 2020-09, Vol.38 (41), p.6374-6380 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2020.08.018 ;PMID: 32798142Full text available |
|
11 |
Material Type: Article
|
Flaviviruses and flavivirus vaccinesVaccine, 2012-06, Vol.30 (29), p.4301-4306 [Peer Reviewed Journal]Elsevier Ltd ;2011 Elsevier Ltd ;Copyright © 2011 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 19, 2012 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2011.09.114 ;PMID: 22682286Full text available |
|
12 |
Material Type: Article
|
Influenza vaccination of health care workers in hospitals—A review of studies on attitudes and predictorsVaccine, 2009-06, Vol.27 (30), p.3935-3944 [Peer Reviewed Journal]Elsevier Ltd ;2009 Elsevier Ltd ;2009 INIST-CNRS ;Copyright Elsevier Limited Jun 19, 2009 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2009.03.056 ;PMID: 19467744 ;CODEN: VACCDEFull text available |
|
13 |
Material Type: Article
|
Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemicVaccine, 2020-10, Vol.38 (45), p.7002-7006 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;Attribution - NonCommercial ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2020.09.041 ;PMID: 32988688Full text available |
|
14 |
Material Type: Article
|
Meningococcal disease: Clinical presentation and sequelaeVaccine, 2012-05, Vol.30, p.B3-B9 [Peer Reviewed Journal]Elsevier Ltd ;2011 Elsevier Ltd ;Copyright © 2011 Elsevier Ltd. All rights reserved. ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2011.12.062 ;PMID: 22607896Full text available |
|
15 |
Material Type: Article
|
Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?Vaccine, 2020-09, Vol.38 (42), p.6500-6507 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2020.08.043 ;PMID: 32863069Full text available |
|
16 |
Material Type: Article
|
Vaccination coverage and immunity levels against vaccine-preventable diseases in male Air Force recruits in GreeceVaccine, 2020-01, Vol.38 (5), p.1181-1185 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2019.11.021 ;PMID: 31761499Full text available |
|
17 |
Material Type: Article
|
The public health value of vaccination for seniors in EuropeVaccine, 2018-05, Vol.36 (19), p.2523-2528 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited May 3, 2018 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2018.03.053 ;PMID: 29615269Full text available |
|
18 |
Material Type: Article
|
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United StatesVaccine, 2012-09, Vol.30 (42), p.6016-6019 [Peer Reviewed Journal]2012 ;Published by Elsevier Ltd. ;Copyright Elsevier Limited Sep 14, 2012 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2012.07.056 ;PMID: 22867718Full text available |
|
19 |
Material Type: Article
|
Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2Vaccine, 2008-06, Vol.26 (27), p.3443-3451 [Peer Reviewed Journal]Elsevier Ltd ;2008 Elsevier Ltd ;2008 INIST-CNRS ;Copyright Elsevier Limited Jun 25, 2008 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2008.04.032 ;PMID: 18513842 ;CODEN: VACCDEFull text available |
|
20 |
Material Type: Article
|
The impact of export regulations on recombinant viral vaccine development for emerging infectious diseasesVaccine, 2020-10, Vol.38 (46), p.7198-7200 [Peer Reviewed Journal]2020 Elsevier Ltd ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2020.09.057 ;PMID: 33032845Full text available |